Rugby player receives sanction
Sport Integrity Australia acknowledges the decision of Rugby Australia to sanction athlete Liam Moseley for the presence of a metabolite of a prohibited substance and the use of a prohibited substance.
Mr Moseley returned an Adverse Analytical Finding (AAF) from an out-of-competition doping control test on 1 April 2021.
His sample detected the presence of Di-hydroxy LGD-4033. It was determined that Mr Moseley used a prohibited substance, namely LGD-4033, on and/or before 1 April 2021 (Use).
LGD-4033 (Ligandrol) is listed under Class S1 (Anabolic Agents) of the Prohibited List and is prohibited at all times.
Rugby Australia imposed a three (3) year ban on Mr Moseley commencing on 1 April 2021.
Mr Moseley is ineligible to participate in any sports that have adopted a World Anti-Doping Code compliant anti-doping policy until 1 April 2024.
ADDITIONAL INFORMATION ON THE PROHIBITED SUBSTANCE
LGD-4033 is promoted as a selective non-steroidal anabolic agent. It is claimed to be a substance that induces muscle (and bone) growth without the side effects associated with steroid use. However, information on the safety of LGD-4033 is scarce due to a lack of medium and long-term clinical trials - hence the medium and long-term health impacts are unknown.
It should be noted that a number of Selective Androgen Receptor Modulators (SARMs) have associated health-risks, particularly for the heart and liver.
Sport Integrity Australia is committed to protecting the right of clean athletes to fair competition. If you are aware of any suspicious doping activity, you can report it anonymously via the Sport Integrity Australia website or call: 1300 027 232.
Sport Integrity Australia recommends athletes check substances and medications before taking them and to follow our advice on any sport supplements.
The Sport Integrity app provides a useful resource for athletes and support staff to check substances and medications. Additionally, it provides information on how to find batch-tested supplements or see if a Therapeutic Use Exemption (TUE) is required.